Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Selectively targeting the cannabinoid receptor CB2 is an attractive therapeutic strategy for the treatment of inflammatory pain without psychiatric side effects mediated by the cannabinoid receptor CB1. Herein, we report the discovery of 4-(1,2,4-oxadiazol-5-yl)azepan-2-one derivatives as a new class of CB2 agonists. Systematic structure-activity relationship investigations resulted in the identification of the most potent compound 25r. This compound displayed high selectivity for CB2 against CB1 (CB2 EC50 = 21.0 nM, Emax = 87%, CB1 EC50 > 30 μM, ratio CB1/CB2 > 1428) with favorable pharmacokinetic properties. Especially, 25r demonstrated significant efficacy in the analgesic model of rodent inflammatory pain. All the results suggest that compound 25r could serve as a lead compound for treating inflammatory pain and deserves further in-depth studies.


Jinshan Nan, Jingming Liu, Guifeng Lin, Shanshan Zhang, Anjie Xia, Pei Zhou, Yangli Zhou, Jiahao Zhang, Jinlong Zhao, Shiyu Zhang, Chong Huang, Yifei Wang, Qian Hu, Junxian Chen, Mingli Xiang, Xin Yang, Shengyong Yang. Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain. Journal of medicinal chemistry. 2023 Mar 09;66(5):3460-3483

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36821347

View Full Text